Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data VITASPRING BIOMEDICAL CO. LTD. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2021
FY2023
FY2024
FY2025
FY2026
Revenue
0
0.02
0.02
0.02
0.25
5.61
0
0
0
0
Cost of revenue
0
0
0
0.01
0.14
3.55
3.33
0
0
0
Gross profit
0
0.01
0.01
0
0.11
2.07
-3.33
0
0
0
Selling, general and administrative
0.04
0.02
0.54
0.94
0.84
1.12
0.68
0.39
Selling and marketing
0.01
0
General and administrative
0
0.02
0.04
0.02
0.54
0.94
0.84
Operating expenses
-0
-0.02
-0.04
Operating income
-0.01
-0.02
0.01
0.43
1.13
-4.18
-1.12
-0.68
-0.39
Other non-operating income
0
0.01
0
0
-4.16
0
Pre-tax income
-0.02
0.01
-0.43
1.13
-4.17
-1.12
-0.68
-0.39
Income tax
0
0
0
0.22
-0.01
0
0.1
0.03
Income from continuing operations
-0.08
Net income
-0
-0.01
-0.02
0.01
0.43
0.91
-4.16
-1.12
-0.77
-0.42
EBITDA
-0.01
-0.02
0.01
0.43
1.14
-4.16
-1.1
-0.67
-0.38
EPS, basic
0.00
0.00
0.00
0.00
0.00
EPS, diluted
0.00
0.00
0.00
0.00
0.00
0.00
-0.02
-0.01
0.00
0.00
Shares, basic (weighted)
91.1
206
Shares, diluted (weighted)
0.05
2.29
9.82
10.9
91.1
206
207
207
207
207
Balance sheet
FY2018
FY2018
FY2019
FY2020
FY2021
FY2021
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
0
0.01
0
0
0.05
0.11
0.03
0
0
0
Receivables
2.95
0.38
0
0
Inventory
0.14
0
0
Other current assets
0
0
0.01
0
0
0.03
0
0
0.01
Total current assets
0
0.01
0.01
0.19
0.19
3.06
0.44
0.02
0
0.01
Property, plant and equipment
0
0
0
0.06
0.05
0.02
0.01
0
Lease right-of-use assets
0.46
0.26
0.09
0
0
Total assets
0
0
0
0.19
0.19
3.6
0.77
0.14
0.01
0.01
Accounts payable
0
0
0
0
0
1.25
2.41
2.41
2.41
2.41
Accrued liabilities
0
0.01
0.02
0.09
0.09
0.48
Total current liabilities
0
0.02
0.02
0.09
0.09
1.74
3.07
3.49
4.03
4.45
Lease liabilities
0.28
0.09
0
0
Total liabilities
0
0.01
0.01
0.1
0.09
2.03
3.16
3.49
4.03
4.45
Paid-in capital
0
0
0.02
0.81
0.81
0.78
0.97
1.14
1.25
1.25
Retained earnings
-0.03
-0.45
0.45
0.78
-3.39
-4.51
-5.28
-5.7
Shareholders' equity
0
-0
-0.01
0
0.1
1.58
-2.4
-3.35
-4.02
-4.43
Minority interests
0.29
0.14
Total equity
0
-0
-0.01
0
0.39
1.58
-2.4
-3.35
-4.02
-4.43
Total liabilities and equity
0
-0
-0.01
0.19
0.19
3.6
0.77
0.14
0.01
0.01
Shares outstanding
3
10.9
210
210
119
152
207
207
Cash flow statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2021
FY2023
FY2024
FY2025
FY2026
Net income
-0
-0.01
-0.02
0.01
0.43
0.91
-4.16
-1.12
-0.77
-0.42
Depreciation and amortization
0
0
0
0
0
0.01
0.02
0.02
0.01
0.01
Stock-based compensation
0.43
0.17
0.19
0.16
0.11
0
Deferred income tax
0.01
-0.01
0
Change in receivables
-2.95
2.54
0.38
0
Change in inventory
-0.14
0.14
0
Change in payables
0
0
-0
0
0
1.25
1.18
Cash from operations
-0
0
-0.03
-0
-0.04
-0.27
-0.08
-0.03
-0.01
-0
Capital expenditures
-0.07
0
Cash from investing
0
-0
0
-0.07
0
Stock issued
0
0
0.02
0
0.01
0.05
0
Cash from financing
0
0.01
0.03
0
0.09
0.05
0
0.01
0.01
0
Net change in cash
-0.01
-0
0.05
-0.29
-0.08
-0.03
0
0
Free cash flow
-0.34
-0.08
Interest paid
0
0
0
0
0
0
0
0
0
0
Income taxes paid
0
0
0
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.01 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-3,074.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
2.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-73.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-40.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
17.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.01x
Current assets / current liabilities.
Quick ratio
0.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.02
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/OCF
217x
Market cap / cash from operations, when positive.
Earnings yield
-19.8%
Net income / market cap (the inverse of P/E).
What was VITASPRING BIOMEDICAL CO. LTD.'s revenue in fiscal 2026?
VITASPRING BIOMEDICAL CO. LTD. reported revenue of $0.0 for fiscal 2026.
Was VITASPRING BIOMEDICAL CO. LTD. profitable in fiscal 2026?
No. It reported a net loss of $415.4K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.